Glucokinase
GCKgeneGCK variants modulate cardiometabolic risk through altered glucose homeostasis and insulin secretion affecting MI susceptibility.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleCardiometabolic risk regulator; associates with MI via glucose metabolism and metabolic syndrome, not atherothrombotic cascade.
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I28
C — non-Type-I56
A — assay feasibility52
E — evidence strength21
T1DI (composite)4
Specificity differential (R−C)-28.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Transcriptome-wide Mendelian randomization during CD4T cell activation reveals immune-related drug targets for cardiometabolic diseases.Nature communications · 2024 · PMID 39468075 · doi